Díaz-Jaimes E, Peñaloza-Ochoa L, Parada-Onoko PM

Language: Spanish
References: 20
Page: 529-536
PDF size: 125.50 Kb.

ABSTRACT

Background: Vincristine is among the drugs used for the treatment of patients with acute lymphoblastic leukemia (ALL). Because it is time- and dose-dependent, it is a drug whose most-feared effect is affectation of the peripheral nerves. It produces long-term physical incapacity that limits activities of daily living. We undertook this study to demonstrate that ALL patients who were enrolled in a supervised program of physical therapy presented confirmed improvement using the nerve conduction velocity (NCV) test of motor and sensorial nerves.
Methods: This was an experimental, comparative, longitudinal, and prospective study carried out in the Department of Rehabilitation of the Hospital Infantil of Mexico «Federico Gomez.» Twenty four patients who fulfilled the inclusion criteria were included. Patients were divided into two groups: group 1–supervised group who received a program of regular, supervised physical therapy for 3 months and group 2–unsupervised group who received a regular program of physical therapy. In both groups, NCV studies were carried out prior to and subsequent to the physical therapy regime. Latency, amplitude and NCV of sensorial and motor nerves of the four extremities were compared.
Results: The peroneal nerve was affected in 98% of the cases and axonal degeneration was the most frequent neuropathy appearing in 96% of subjects. Relationship of the results obtained in the NCV studies (both prior and subsequent) in both groups was statistically nonsignificant (P ›0.01), whereas the relationship of the NCV studies between groups was statistically significant (P ‹0.01). Under appropriate supervision and monitoring, the physical therapy program for patients with leukemia and neuropathy treated regularly with vincristine displays major benefits that are able to be measured objectively by NCV studies.

REFERENCES

1. Cervera Bravo A. Cáncer. Panorámica general. Aspectos básicos de la epidemiología, etiología, genética y diagnóstico. Pediatría de Atención Primaria 2005;27:63-79.

2. Donat J. Características generales del cáncer pediátrico. Viure en Salut 73 2006;12:4-5.

3. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000;96:24-33.

4. Kara M, Kelly MD. Acute Lymphoblastic Leukemia. Pediatric Hematology/Oncology Secrets. Philadelphia: Hanley and Belfus Inc.; 2002. p. 109-114.

5. Ferro Delgado MT, Cabello Albendea P. Bases genéticas y herencia en oncología pediátrica. Hematología y Oncología Pediátrica. Madrid: Ergon; 2005. p. 239-249.

6. Carroll EL, Bhojwani D, Min DJ, Raetz E, Relling M, Davies S, et al. Pediatric acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2003:102-131.

7. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003;21:3616-3622.

8. Ferrís Tortajada J, Ortega García JA, Marco Macías A, García Castell J. Medio ambiente y cáncer pediátrico. An Pediatr (Barc) 2004;61:42-50.

9. Hutchinson RJ, Gaynon PS, Sather H, et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children´s Cancer Group Trial 1881. J Clin Oncol 2003;21:1790-1797.

10. Bromberg MB. Peripheral neurotoxic disorders. Clin Neurobehav Toxicol 2000;18:681–689

11. Postma TJ, Heimans JJ. Chemotherapy-induced peripheral neuropathy. The impact of chemotherapy induced peripheral neuropathy, clinical studies and quality of life. Thela Thesis, Amsterdam; 1998. p 7–12

12. Kimura J. Polyneuropathies: Electrodiagnosis in diseases of nerve and muscle. Principles and Practice. Philadelphia: FA Davis. 1989; p 462-481.

13. Carbone PP, Bono V, Freie E, Brindley CO. Clinical studies with vincristine. Blood 1963;21:640–647

14. Harila-Saari A, Vainionpaa LK, Kovala TT, Tolonen EU, Lanning BM. Nerve lesions after therapy for childhood acute lymphoblastic leukemia. Cancer 1998;82:200-207.

15. Stokes M. Fisioterapia en la Rehabilitación Neurológica. España: Elsevier Mosby.2006; p 277-279.

16. Jones HR, Bolton CF, Harper CM. Pediatric clinical Electromyography. Philadelphia, PA: Lippincott-Raven. 1996: p 21-34.

17. Ueberall MA, Skirl HM. Straûburg DW. Neurophysiological findings in long-term survivors of acute lymphoblastic leukaemia in childhood treated with the BFM protocol 81 SR-A/B. Eur J Pediatr 1997;156:727-733.

18. Hartman A, Van den Bos C, Stijnen T, Pieters R. Decrease in motor performance in children with cancer is dependent of the cumulative dose of vincristine. Cancer 2006;106:226-232.

19. Verstappen CCP, Koepen S, Heimans JJ, Huigene PC, Scheulsen ME, Strumber D, Kiburg B, Postman TJ. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurol 2005;64:1076-1077.

20. Vainionpaa L, Kovala T, Tolonen U, Lanning M. Vincristine therapy for children with acute lymphoblastic leukemia impairs conduction in the entire peripheral nerve. Pediatr Neurol 1995;13:314-318.